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Abstract
Background: Caesarean section is one of the most commonly performed operations on women throughout the world. Rates
have increased in recent years – about 20–25% in many developed countries. Rates in other parts of the world vary widely.
A variety of surgical techniques for all elements of the caesarean section operation are in use. Many have not yet been rigorously
evaluated in randomised controlled trials, and it is not known whether any are associated with better outcomes for women and
babies. Because huge numbers of women undergo caesarean section, even small differences in post-operative morbidity rates
between techniques could translate into improved health for substantial numbers of women, and significant cost savings.
Design: CORONIS is a multicentre, fractional, factorial randomised controlled trial and will be conducted in centres in
Argentina, Ghana, India, Kenya, Pakistan and Sudan.
Women are eligible if they are undergoing their first or second caesarean section through a transverse abdominal incision.
Five comparisons will be carried out in one trial, using a 2 × 2 × 2 × 2 × 2 fractional factorial design. This design has rarely been
used, but is appropriate for the evaluation of several procedures which will be used together in clinical practice. The
interventions are:
• Blunt versus sharp abdominal entry
• Exteriorisation of the uterus for repair versus intra-abdominal repair
• Single versus double layer closure of the uterus
• Closure versus non-closure of the peritoneum (pelvic and parietal)
• Chromic catgut versus Polyglactin-910 for uterine repair
The primary outcome is death or maternal infectious morbidity (one or more of the following: antibiotic use for maternal febrile
morbidity during postnatal hospital stay, antibiotic use for endometritis, wound infection or peritonitis) or further operative
procedures; or blood transfusion.
The sample size required is 15,000 women in total; at least 7,586 women in each comparison.
Discussion: Improvements in health from optimising caesarean section techniques are likely to be more significant in developing
countries, because the rates of postoperative morbidity in these countries tend to be higher. More women could therefore
benefit from improvements in techniques.
Trial registration: The CORONIS Trial is registered in the Current Controlled Trials registry. ISCRTN31089967.
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Caesarean section is one of the most commonly per-
formed abdominal operations on women in most coun-
tries of the world. Rates have increased markedly in recent
years, and are about 20–25% in many developed coun-
tries [1,2]. The rates in other parts of the world vary
widely, from 1.6% in Haiti to 59% in Chilean private hos-
pitals [3].
According to a population-based cross sectional study in
Madras, India [4], caesarean section rates in the public,
charitable and private sectors were 20%, 38% and 47%
respectively, and the total population caesarean section
rate was 32.6% with a primary caesarean section rate of
25%. With a private sector that accounts for 50–70% of
patient care currently, and public sector health financing
decreasing, the private sector is likely to dominate health
care in India in the future, which means that the general
rate of caesarean section will rise substantially. This rising
trend is being observed in many other countries.
A variety of surgical techniques for all elements of the cae-
sarean section operation are in use [5]. Many of these have
not yet been rigorously evaluated in randomised control-
led trials, and it is not known whether any are associated
with better outcomes for the women and babies. Because
of the huge number of women that undergo caesarean
section, even small differences in post-operative morbid-
ity rates between techniques could translate into
improved health for a substantial number of women, and
significant savings of costs and resources for health serv-
ices. It is therefore important that caesarean section oper-
ations are performed as safely and effectively as possible
and that methodologically rigorous randomised control-
led trials are performed to establish the effectiveness of
different surgical techniques.
Improvements in health from optimising caesarean sec-
tion techniques are likely to be more significant in devel-
oping countries, because the rates of postoperative
morbidity in these countries tend to be higher. More
women could therefore benefit from improvements in
techniques.
The aim of this study is to examine five specific aspects of
caesarean section technique to help determine which
methods lead to an optimum outcome for women and
their babies.
These interventions are:
1. Blunt versus sharp abdominal entry
2. Exteriorisation of the uterus for repair versus intra-
abdominal repair
3. Single versus double layer closure of the uterus
4. Closure versus non-closure of the peritoneum (pelvic
and parietal)
5. Chromic catgut versus Polyglactin-910 for uterine
repair
Techniques for caesarean section
Blunt versus sharp abdominal entry (Table 1)
A protocol for a systematic review of abdominal incisions
for caesarean section has been published in the Cochrane
Library, and the full review is in progress [6].
Three randomised controlled trials have been published
that compared the 'blunt' (sometimes referred to as the
Joel-Cohen) method of abdominal entry with the 'sharp'
(sometimes referred to as the Pfannenstiel) incision. The
study by Decavalas et al [7] which included 268 women
was only reported in abstract form and therefore few
details of the methodology were available. The outcomes
reported suggested a reduction in operating time, an
improvement in a composite measure of maternal mor-
bidity (unspecified) and fewer adhesions when a repeat
operation was performed, with the Joel-Cohen method.
The study by Mathai et al [8] randomised 101 women and
found a marked improvement in the need for analgesia in
the first four postoperative hours, a shorter operating time
and lower febrile morbidity with the Joel-Cohen tech-
nique. This study used a standard spinal anaesthetic for all
women to make comparisons of analgesic requirements
Table 1: Blunt versus sharp abdominal entry
Study n Infection Pain Health service use Other outcomes
Outcome Result Outcome Result Outcome Result Outcome Result
Decavalas7 268 Operating time 
(mean)
26 v 35 min Composite 
morbidity (RR)
0.51
(0.24, 1.05)
Mathai et al8 101 Febrile 
morbidity (RR)
0.25
(0.07, 0.82)
Analgesia in 
first 4 hours 
post op (RR)
0.55
(0.40, 0.76)
Operating time 
(mean (SD))
33 (7.8) v 44 
(16.9) min
Franchi et al9 310 Operating time 
(median 
(range))
30 (12–60) v 32 
(18–70) min
Composite 
morbidity (RR)
0.94
(0.39, 2.24)Page 2 of 17
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which included 310 women, found no difference between
the Joel-Cohen and Pfannenstiel groups.
Overall, these studies, which recruited a total of 679
women, may suggest some benefits of the Joel-Cohen
approach, but they have not yet been formally synthesised
in a systematic review, and there appear to be unexplained
inconsistencies between the results of the three studies.
A number of randomised trials have evaluated combina-
tions of techniques, such as the Misgav-Ladach method
for caesarean section and are the subject of a Cochrane
systematic review which is in protocol stage [10]. These
frequently compare a method involving blunt abdominal
entry with one using sharp abdominal entry. However,
the techniques being compared also differ in other
respects (such as single or double layer uterine closure and
whether or not the peritoneum is closed) and therefore it
is not possible to separate the effects of blunt or sharp
abdominal entry from those of the other techniques.
These trials therefore do not provide any information rel-
evant to this comparison.
Exteriorisation of the uterus for repair versus intra-
abdominal repair (Table 2)
The Cochrane systematic review comparing exteriorisa-
tion with intraperitoneal repair found six trials with 1294
women in total [11].
This review suggested a reduction in early febrile morbid-
ity in the exteriorisation group. Although this finding was
statistically significant (RR 0.41, 95% CI 0.17–0.97), these
results were based on only one trial of 308 women, which
was of poor methodological quality. The length of hospi-
tal stay was found to be marginally longer in the exterior-
isation group in the four trials assessing this outcome
(WMD 0.24 days, 95% CI 0.08–0.39), which may not
have much clinical significance. No difference in the inci-
dence of endometritis or wound infection was found
between the two groups.
Pain was addressed by only one study [12], and this used
6 different scoring systems to do so. One of these showed
a statistically significantly difference between groups, but
a more reliable measurement may have been a statistical
test incorporating all six readings into one test.
Overall the evidence for the harms or benefits of exterior-
isation of the uterus for repair is poor due to the small size
of the studies and the diversity of the outcomes examined.
Closure versus non-closure of the peritoneum (pelvic and 
parietal) (Table 3)
The Cochrane review of closure versus non-closure of the
peritoneum, visceral and/or parietal peritoneum was last
updated in 2003. It incorporates nine trials including
1,811 women comparing non-closure versus closure of
the visceral and/or the parietal peritoneum [13]. This
review found that non-closure was associated with a
reduction in operating time (WMD -7.33 mins, 95% CI -
8.43, -6.24) and postoperative fever (RR 0.66, 95% CI
0.46, 0.95), but no significant difference in the number of
analgesic doses (WMD -0.29, 95% CI -0.69, 0.12), wound
infection (RR 0.60, 95% CI 0.29, 1.21) or endometritis
(RR 1.30, 95% CI 0.62, 2.71). However, the trials were
generally small and of variable methodological quality;
three of them used quasi-randomisation methods and
hence did not have secure concealment of allocation, ren-
dering them at high risk of bias.
A long-term follow-up study of one of the trials included
in the Cochrane review has also been published [14]. 144
out of 280 women originally randomised were included
in this study (51%). There were no differences in fertility,
abdominal pain, urinary symptoms, or adhesions at sub-
sequent surgery, but the small sample size would be very
unlikely to detect any but the largest differences.
These studies suggest that non-closure of the peritoneum
may carry some short-term advantages, including a lower
risk of post-operative infection, shorter operating time
and shorter hospital stay. Again, however, the studies
identified were small and the methodology was not
always strong.
Table 2: Exteriorisation of the uterus for repair versus intra-abdominal repair
Study n Infection Wound complications Blood loss Health service use
Outcome Result Outcome Result Outcome Result Outcome Result
Cochrane 
review11
1,294 Fever (>3 days) 
(n = 308) (RR)
0.41
(0.17, 0.97)
Infection, 
haematoma, 
breakdown
(n = 735) (RR)
0.88
(0.53, 1.46)
Vol blood lost
(n = 504) (WMD)
17.11 (-23.15, 
57.37) ml
Hospital stay
(n = 766) 
(WMD)
0.24
(0.08, 0.39) 
days
Endometritis
(n = 592) (RR)
1.29
(0.64, 2.60)
Drop in 
haematocrit
(n = 324) (WMD)
-0.47
(-1.48, 0.54)%Page 3 of 17
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The Cochrane systematic review of single versus double
layer closure of the uterine incision includes two trials
which involve 1006 women in total, although each out-
come has data from only one trial [15]. This review has
not been updated since 1996, but a protocol for an
updated and revised review has been published and the
review is in progress [16]. Two further trials comparing
single and double layer uterine closure published since
the Cochrane review was last updated was identified,
involving 333 women [17,18]. None of the existing stud-
ies suggests major differences in outcomes between single
and double layer uterine closure.
Chapman et al [19] measured maternal outcomes in the
subsequent pregnancy of women included in one of the
studies in the Cochrane review. There was no detectable
difference in the length of labour, mode of delivery, risk
of scar dehiscence or haemorrhage between the two
groups. However, the numbers were small and only a
small proportion of the women randomised could be
included in this follow-up study (145 women followed up
out of a total study population of 906 women).
Two observational studies of the long-term effects of sin-
gle and double layer uterine closure have been published
[20,21]. Bujold et al examined a retrospective cohort of
2,142 women from one hospital in Canada who had
undergone a trial of labour following a single previous
lower segment caesarean section between 1988 and 2000.
The main finding was an increased risk of uterine rupture
with previous single layer closure. However, other differ-
ences may account for the differences in outcome in this
observational study. For example, the caesarean technique
used changed from mainly double layer closure to mainly
single layer closure during the period studied, and the
selection criteria for trial of labour may have changed in
this time too. Thus women who had single layer closure
Table 4: Single versus double layer closure of the uterus
Study n Infection Blood loss Health service use Other outcomes
Outcome Result Outcome Result Outcome Result Outcome Result
Cochrane 
review15
1,006 Endometritis 
(n = 784) (RR)
1.22
(0.91–1.63)
Transfusion
(n = 906) (RR)
0.80
(0.34–1.92)
Operating time 
(Mean)
43.8 v 47.5 min Moderate or 
major 
deformity of
0.19
(0.06–0.60)
Extra 
haemostatic 
sutures
(n = 906) (RR)
0.93
(0.79–1.08)
scar on 
radiography
(n = 100) (RR)
>8% drop in 
haematocrit
(n = 906) (RR)
1.09
(0.86–1.38)
Heidenreich1
7
125 Post-operative 
fever
4.8% v. 7.2% Transfusion 3.8% v. 3.2% Scar thickness 
by US (8–10 
days after 
surgery)
0.72 v. 0.82 cm
Sood18 208 Febrile 
morbidity (RR)
0.50
(0.27–0.94)
Intraoperative 
blood loss 
(Mean)
600 v. 629.6 ml Operating time 
(Mean)
Hospital stay 
(Mean)
31.3 v. 33.1 min
6.67 v. 7.19 
days
Pain (VAS 
Score) (Mean)
2.91 v. 3.05
Endometritis 
(RR)
0.44
(0.20–0.95)
Additional 
suture (RR)
1.36
(0.85–2.17)
Wound 
infection (RR)
0.46
(0.15–1.45)
Table 3: Closure versus non-closure of the peritoneum
Study n Infection Blood loss Health service use Other outcomes
Outcome Result Outcome Result Outcome Result Outcome Result
Cochrane 
review13
1,811 Postoperative 
fever (n = 874) 
(RR)
0.66
(0.46, 0.95)
Operating 
Time (n = 974) 
(WMD)
-7.33
(-8.43, -6.24) min
Analgesic dose 
required
(n = 393) (WMD)
-0.29
(-0.69, 0.12)
Endometritis
(n = 474) (RR)
1.30
(0.62, 2.71)
Postoperative 
days in Hospital 
(n = 974) 
(WMD)
-0.39
(-0.51, -0.28)
Wound 
infection
(n = 534) (RR)
0.60 (0.29,1.21)Page 4 of 17
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study's result was not replicated by a second observational
study, which found no increased risk of uterine rupture
with single layer closure [21].
Overall there is little evidence that there is any difference
in short term outcomes between single and double layer
uterine closure. The observational study by Bujold et al
has raised the possibility of an increased risk of uterine
rupture in labour after single layer closure, and further
research using larger, randomised controlled studies is
needed to investigate this possible association.
Chromic catgut versus Polyglactin-910 for uterine repair
Materials for suturing the uterus are included in a recently
published Cochrane review [22]. This review was not able
to identify any published or ongoing trials comparing dif-
ferent suture materials for this element of the caesarean
section operation.
Summary
The existing trials provide only limited evidence about the
advantages and disadvantages for mother and baby of the
different options for the conduct of caesarean sections.
All have sample sizes that are insufficient to detect clini-
cally or economically important differences between the
groups. Given the very high number of caesarean sections
performed, even small differences may be important for
the cost of health services or the population's health. Reli-
able detection of differences of this size is likely to require
a sample size of several thousand, but the largest pub-
lished trial has a sample size of 906 [23].
Many of the trials measure surrogate outcomes such as
duration of operation which may have no correlation
with maternal or neonatal outcome. Substantive meas-
ures of morbidity such as antibiotic use, fever, post-oper-
ative pain and the wellbeing of the infant are more likely
to provide guidance for clinical decisions in the future,
which is why the CORONIS Trial has chosen to measure
these outcomes.
The methodology of the existing trials is generally poor or
inadequately described. For example, quasi-randomisa-
tion by hospital number or date, non-blinded assessment
of outcomes and exclusion of randomised women from
the analysis are found in some of these studies, and all of
these practices could lead to bias. The results reported by
many of the existing studies may therefore be unreliable.
This may be exacerbated by combining such unreliable
studies in meta-analyses, which may in turn give a more
precise but still biased summary.
Objectives
The objectives of the trial are to determine whether there
are any differences in maternal morbidity when compar-
ing the following five pairs of alternative surgical tech-
niques undertaken during the time of caesarean section:
1. Blunt versus sharp abdominal entry
2. Exteriorisation of the uterus for repair versus intra-
abdominal repair
3. Single versus double layer closure of the uterus
4. Closure versus non-closure of the peritoneum (pelvic
and parietal)
5. Chromic catgut versus Polyglactin-910 for uterine
repair
Study design
The study is a multicentre, fractional factorial randomised
controlled trial and will be conducted in centres in the fol-
lowing six countries: Argentina, Ghana, India, Kenya,
Pakistan and Sudan. The collaborating institutions are
centres with experience in conducting trials. These centres
also have experience in detailed follow-up of large num-
bers of women.
The study will not alter or interfere with any treatment or
care given routinely to women in the hospitals where the
caesarean section takes place except on the interventions
to be evaluated.
Factorial design
Factorial trials maximise the efficiency of a trial by includ-
ing more than one trial question into a single trial popu-
lation. Instead of having one trial which compares, for
example, single versus double layer closure of the uterine
incision and another trial comparing closure versus non-
closure of the peritoneum, both comparisons can be com-
bined into one trial using only the number of women nec-
essary to answer one of these questions in isolation.
In the CORONIS Trial five comparisons will be carried out
in one trial, using a 2 × 2 × 2 × 2 × 2 factorial design. Such
a design has rarely been used [24,25], but is appropriate
for the evaluation of several procedures which will be
used together in clinical practice. In this trial of different
caesarean section techniques, using five pairs of possible
allocated interventions (1 versus "not 1", 2 versus "not 2",
3 vs versus "not 3", 4 versus "not 4", 5 versus "not 5"), par-
ticipants can receive one of 32 possible alternatives.
In the analysis of a factorial trial the same process is used
for a 2 × 2 × 2 × 2 × 2 factorial design as for a 2 × 2 factorialPage 5 of 17
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allocated "not 1" regardless of what other interventions
were allocated, provided that there is no interaction. This
is best illustrated using an example. Consider a 2 × 2 fac-
torial trial comparing the effects of single versus double
layer closure of the uterine incision and closure versus
non-closure of the peritoneum. Hence, there are four
groups in the trial:
• single layer and closure of the peritoneum
• single layer and non-closure of the peritoneum
• double layer and closure of the peritoneum
• double layer and non-closure of the peritoneum
A simple example (Table 5) of no interaction being
present. Here, the febrile morbidity risk ratio for double
versus single layer uterine closure is the same in those who
had closure of the peritoneum (20% vs 10% gives risk
ratio = 2) and those who had non-closure (30% vs 15%
gives risk ratio = 2). Therefore, the single layer and double
layer groups may be combined and the analysis is based
on the (bold) marginal totals (25% vs 12.5% gives risk
ratio = 2).
Similarly, Table 6 gives a simple example of an interaction
being present. Here, the febrile morbidity risk ratio for
double versus single layer uterine closure is much smaller
in those who had closure of the peritoneum (10% vs 10%
gives risk ratio = 1) than in those who had non-closure
(40% vs 20% gives risk ratio = 2). Therefore, we would
present these two risk ratios separately rather than using
the combined data.
Fractional Factorial Trials
In a standard 2 × 2 × 2 × 2 × 2 factorial design, all partici-
pants would receive one of 32 possible alternatives, and
each of these alternatives would include five interven-
tions. This study is a fractional factorial design, and, there-
fore, each participant will be allocated only three out of
the five possible interventions. Such an incomplete facto-
rial design was considered appropriate because it allows
five surgical techniques to be tested in the same trial, but
restricts the number of techniques being tested per centre
and per surgeon to three. Hence, each centre needs to
implement training for three (not five) surgical tech-
niques and each surgeon needs to remember the three
(not five) allocated techniques for every randomised
woman. There are two main implications of this incom-
plete factorial design. First, in the study design, we will
ensure that a similar number of women are included in
each of the five comparisons (see later section on Feasibil-
ity). Second, in the analysis, we will not be able to test for
interactions between more than three interventions; this
won't pose a problem because we are only planning to test
for pairwise interactions (see later section on Analysis).
Treatment allocation
Randomised allocation will be achieved by a variety of
methods. For centres with reliable telephone access, there
will be central telephone randomisation, using a web-
based system and a toll-free telephone number. This will
be a 24/7 system which will be attended by the local
Regional Trial Office Co-ordinator during day time hours
and will use a voice recognition system over night. The
system will allocate a number which will correspond to a
series of allocation envelopes held at the participating site.
Each envelope will contain the allocation for a woman
which will be recorded on the data collection form and
the envelope kept for verification.
In centres with unreliable telephone access, the only avail-
able option is to use a sequentially numbered series of
sealed opaque envelopes.
The allocation will be to three options. This will be to one
or other of three of the interventions. For example, the
allocation may be to:
"Sharp abdominal entry; single layer repair of uterus; non-
closure of the peritoneum."
All randomisation data will be recorded and held cen-
trally at the International Co-ordinating Centre in NPEU.
Minimisation
As the sample size of the trial is large, chance imbalances
between groups for major prognostic variables are
unlikely. However, minimisation will be used to ensure
Table 5: Example of no interaction present
Single Double Total
Closure 10/100 (10%) 20/100 (20%) 30/200 (15%)
Non-closure 15/100 (15%) 30/100 (30%) 45/200 (22.5%)
Total 25/200 (12.5%) 50/200 (25%) 75/400 (18.75%)
Numbers shown are number of cases of febrile morbidity/total (percentage)Page 6 of 17
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tant prognostic risk factor: in-labour and not in-labour
caesarean section. In addition, for centres using telephone
randomisation, minimisation will be used to ensure bal-
ance between groups with respect to first or second caesar-
ean section. Regardless of whether the method of
randomisation is by envelope or telephone there will be
balance within centre.
Interventions
There are five pairs of interventions being tested in this
trial; however, each participating hospital will only take
part in three of these five possible comparisons. The non-
allocated comparisons and all other aspects of the caesar-
ean section will be performed at the discretion of the sur-
geon. For example, for women randomised in a hospital
which is taking part in the three comparisons: sharp vs
blunt abdominal entry; double vs single layer uterine clo-
sure; and closure vs non-closure of the peritoneum; then
it will be at the discretion of the surgeon as to whether
there is exteriorisation of the uterus or not, and what
suture material is used for uterine repair.
All allocated techniques should be performed unless there
are overwhelming reasons not to do so. For example, at
the time of surgery it may become apparent that there is
no clear peritoneal layer overlying the uterus in a woman
undergoing a second caesarean section. In these circum-
stances, it will not be possible to close this peritoneal layer
during the repair. Other clinical circumstances may also
change during the course of the surgical procedure after a
particular intervention has been allocated. If the clinician
performing the caesarean section is certain that a non-
allocated intervention is necessary then this should be
performed and the reasons for not complying with the
allocated intervention recorded on the data collection
form.
1. Blunt versus sharp abdominal entry
Sharp abdominal entry
The abdomen is entered using a scalpel to divide the
abdominal skin. Each subsequent layer of the abdomen
(fat, rectus sheath and parietal peritoneum) is then sepa-
rately identified and divided using either a scalpel or scis-
sors.
Blunt abdominal entry
The abdomen is entered using a scalpel to divide the
abdominal skin. The scalpel is then used to divide the fat
and rectus sheath in the midline and the rectus sheath
incision is extended manually (without the use of a scal-
pel or scissors). The parietal peritoneum is then entered
digitally and the defect enlarged manually.
For some women with a previous caesarean section, blunt
abdominal entry may be impeded by scar tissue. If this is
the case, surgeons should use whatever technique is nec-
essary to effect abdominal entry with the minimum of risk
to the well being of the woman. If during the blunt
abdominal entry a scalpel or scissors are used to extend
the original incision in the sheath or peritoneum, then
this should be recorded as a sharp abdominal entry on the
Data Collection Booklet.
2. Exteriorisation of uterus for repair versus intra-
abdominal repair
Exteriorisation
Once the placenta has been delivered the uterus is drawn
from the pelvis to rest on the anterior abdominal wall so
that the uterine incision can clearly be visualised. The
uterus is then repaired (with or without repair of the pel-
vic peritoneum) and the uterus is then returned to the pel-
vis.
If exteriorisation of the uterus is not possible because of
pain, then intra-abdominal repair may be necessary. This
should be recorded as intra-abdominal repair on the Data
Collection Booklet and the reason for non-compliance
with the allocated intervention given as "intra-operative
pain".
Intra-abdominal repair
The uterine incision is repaired while in the pelvis.
3. Single versus double layer closure of the uterus
Double layer uterine closure
The uterine incision is closed with two layers of sutures.
Each layer may be continuous, continuous locking, inter-
rupted or any other accepted technique.
The first layer opposes the endometrial aspect of the uter-
ine muscle layer and the second layer of sutures bring
Table 6: Example of interaction present
Single Double Total
Closure 10/100 (10%) 10/100 (10%) 20/200 (10%)
Non-closure 20/100 (20%) 40/100 (40%) 60/200 (30%)
Total 30/200 (15%) 50/200 (25%) 50/400 (12.5%)
Numbers shown are number of cases of febrile morbidity/total (percentage)Page 7 of 17
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plete apposition of the incision.
Single layer uterine closure
This technique involves bringing both edges of the uterine
incision together with a single layer of sutures. This may
be a continuous, continuous locking or an interrupted
layer of sutures.
Haemostasis of the incision can be effected by using addi-
tional single or 'figure of eight' sutures as judged necessary
by the surgeon regardless of the method of closure under-
taken.
4. Closure or non-closure of the peritoneum
Closure of the peritoneum
Women allocated closure of the peritoneum should have
the pelvic and parietal peritoneum closed. The techniques
of closure, including the suture material used, will be at
the discretion of the clinician.
In some women with a previous caesarean section, repair
of the pelvic peritoneum, the parietal peritoneum or both
may be impossible. If this is the case, surgeons should
record this as non-closure of the peritoneum on the Data
Collection Booklet including the reason for non-compli-
ance.
Non-closure of the peritoneum
In women allocated non-closure, the peritoneum should
not be closed.
For either closure or non-closure of the peritoneum, hae-
mostasis should be affected as usual including, where nec-
essary, the use of haemostatic sutures.
5. Chromic catgut versus Polyglactin-910 for uterine repair
Chromic catgut
The uterus will be repaired using No. 1 chromic catgut.
This may be a continuous, continuous locking or an inter-
rupted layer of sutures.
Polyglactin-910
The uterus will be repaired using No. 1 Polyglactin-910.
This may be a continuous, continuous locking or an inter-
rupted layer of sutures.
Haemostasis of the incision can be effected by using addi-
tional single or 'figure of eight' sutures as judged necessary
by the surgeon.
Regardless of the type of suture material allocated, any
unused sutures should not be used to effect repair of any
other tissue layer. The standard materials used in each
centre should be used to close the peritoneum (if per-
formed), the sheath, the subcutaneous tissue (if closed)
and the skin.
Use of the allocated suture material to close other tissue
layers will render the randomised comparison of Polygla-
ctin-910 versus chromic catgut invalid (particularly if
there is differential use, i.e. the Polyglactin-910 is used
and the chromic catgut is not used to close the sheath).
Other aspects of clinical management
All other aspects of the operation, apart from those ran-
domly allocated, will be determined by the attending sur-
geon and anaesthetist including the choice of suture
materials and the techniques for repair used.
Women participating in the trial will be managed in what-
ever way seems best for them. Participation in the trial
does not restrict the use of any other therapeutic or diag-
nostic procedures judged necessary by the attending clini-
cian. This applies particularly to the use of analgesia,
perioperative antibiotics or thromboprophylaxis. Current
hospital practice should be continued, regardless of par-
ticipation in the trial.
It is essential that the other aspects of the caesarean sec-
tion operation remain constant regardless of those aspects
which are allocated. So, for example, if it is the usual prac-
tice of the surgeon to infiltrate the skin edges with local
anaesthetic for post-operative analgesia, this should con-
tinue for all women operated on by that surgeon regard-
less of whether the women is allocated sharp or blunt
abdominal entry. The use of other interventions, such as
per-rectum analgesia, should similarly be the same for
women in each allocated group. Differential use of these
co-interventions between randomised groups will render
the comparisons of the trial invalid.
Training in surgical techniques
Of the techniques being compared, training may be
required in single or double layer uterine closure and in
blunt and sharp abdominal entry. All the other techniques
are familiar to all obstetricians in clinical practice in the
participating centres.
Each participating centre will initiate, maintain and docu-
ment a training programme which ensures that all person-
nel involved in the undertaking of caesarean sections are
familiar with the techniques being compared before they
enter women into the trial. Training will vary between
countries according to the national standards of training
in new surgical techniques employed by each participat-
ing country. For example, if the accepted standard for sur-
gical training in a country is that operators must perform
a certain number of procedures before they are judged to
be competent in that procedure, then this process shouldPage 8 of 17
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operators are judged to be competent when a senior sur-
geon judges them to be competent, then this process
should be followed. The accepted standard of surgical
training in each centre will be determined at the start of
the trial and specific documentation will be produced for
each country to facilitate the recording of details of each
operator 'accredited' to operate on women recruited to the
trial. To facilitate training a film of all the interventions
being tested in CORONIS will be provided to participat-
ing centres. In individual countries, visits by the Regional
Co-ordinator to participating hospitals to teach specific
surgical techniques may be required so that experience in
the participating hospitals can be disseminated rapidly.
Each participating centre will appoint a senior obstetri-
cian to ensure that only clinical staff competent in the var-
ious surgical techniques to be used in the trial are
'authorised' to operate. A list of these personnel will be
kept by the local centre with a copy being kept by each
Regional Trial Office.
Trial eligibility
Women ARE eligible for trial entry if:
• They are undergoing delivery by lower segment Caesar-
ean section through a transverse abdominal incision, irre-
spective of fever in labour, gestational age or whether they have
a multiple pregnancy.
Women are NOT eligible if :
• There is a clear indication for a particular surgical tech-
nique or material to be used that prevents any of the allo-
cated interventions being used,
e.g. for a woman with a previous vertical abdominal incision it
maybe considered inappropriate to do a transverse abdominal
incision for this caesarean section. However, if a transverse
incision is going to be performed the woman is eligible.
• They have had more than one previous caesarean sec-
tion.
• They have already been recruited into the trial during a
previous pregnancy.
Trial entry and consent
Each participating country and hospital, with advice from
their research ethics committee, will decide how best to
provide information to women about the trial and seek
informed consent.
Information leaflets will be made available to local cen-
tres, in appropriate languages, which explain the justifica-
tion for the trial, the process of trial entry and follow up.
Once a woman becomes eligible, the trial should be dis-
cussed with her (and her partner as appropriate).
During this discussion the following points should be
addressed:
• that consent is being sought for the woman's participa-
tion in a randomised controlled trial;
• the trial will compare different aspects of the caesarean
section techniques, all of which are in common practice
throughout the world;
• that the aspects being compared will be allocated at ran-
dom;
• that participation in the trial is voluntary and declining
to enter the trial will not affect the quality of the medical
care the woman receives;
• that one hospital visit or home visit is required at six
weeks after the birth of her baby;
• that she is free to withdraw her consent to participate in
the trial at any time.
All women will be required to sign a formal consent form
if they agree to participate in the trial. If women are not
able to sign a consent form, the method of recording con-
sent which is currently used in that setting will be used for
the trial (for example, the recording of a thumb print from
the woman on the consent form). If there is no objection
to trial entry, a few brief details will then be recorded on
the trial data collection form.
This information is collected for three reasons:
i. to check eligibility,
ii. to enable later (unbiased) description of the women
studied,
iii. to assist follow-up.
Measurement of outcomes
Primary outcome
1. Death or maternal infectious morbidity (one or more of
the following: antibiotic use for maternal febrile morbid-
ity during postnatal hospital stay, antibiotic use for
endometritis, wound infection or peritonitis) or further
operative procedures; or blood transfusion.
Note: although there are concerns about the use of composite
outcomes, we believe that the advantage of increased precisionPage 9 of 17
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disadvantages. All the outcomes included in this composite are
associated with the primary objective of the trial and are likely
to act in the same direction as each other thereby preventing
any dilution of the treatment effect.
Secondary outcomes – all within 6 weeks of delivery unless 
stated otherwise
Clinical
1. Death.
2. Febrile morbidity.
Note: any clinical diagnosis of fever >38°C made by a health
professional and treated with antibiotics during postnatal hos-
pital stay.
3. Endometritis.
Note: any clinical diagnosis of endometritis made by a health
professional and treated with antibiotics during the first six
weeks after the caesarean section. For events which occur after
discharge from hospital this information will be gathered by
interview with each woman six weeks after the caesarean sec-
tion.
4. Wound infection treated with antibiotics.
Note: any antibiotics prescribed specifically for a wound infec-
tion. This information will be gathered by interview with each
woman at six weeks after the caesarean section.
5. Operative procedures on wound.
Note: this will include any procedures on the wound because of
infection, dehiscence or haematoma within the first six weeks
following delivery.
6. Pain.
Note: this will be a subjective assessment of post-operative pain
by the women at the time of hospital discharge and at six weeks.
In addition a category of 'severe pain' will be recorded if the
woman is prescribed additional analgesia over and above rou-
tine 24–48 hours after surgery.
7. Blood transfusion.
8. Interventions used for severe primary post-partum
haemorrhage (PPH).
Note: this is defined as women who (a) require additonal uter-
otonics over and above routine, (b) where a brace suture is used
(eg. B-Lynch suture), (c) where internal iliac artery, or other
major artery, ligation is performed, (d) where balloon tampon-
ade or uterine packing is performed or (e) where a hysterectomy
is performed.
9. Stillbirth after trial entry.
Note: it is possible that a delay in abdominal entry associated
with different methods may adversely affect neonatal outcome.
10. Apgar score < 3 at five minutes.
11. Laceration of baby at time of caesarean section.
12. Death of the baby by six weeks of age.
13. Other severe maternal morbidity.
Note: this will include events such as peritonitis, severe second-
ary post-partum haemorrhage, deep venous thromboses, pulmo-
nary embolism, and sepsis within six weeks of delivery, etc.
Health Service Utilisation
14. Duration of operation (from incision to closure).
15. Duration of hospital stay post-caesarean section.
16. Duration of stay in Intensive Care Unit post-caesarean
section.
17. Number and duration of re-admissions to hospital
within 6 weeks of the caesarean section.
Data collection
Information will be collected at the following times:
• at trial entry;
• immediately following the operation;
• at discharge from hospital (including transfer to another
hospital);
• at six weeks after delivery.
Information at trial entry including eligibility and mater-
nal characteristics will be collected from the hospital
notes onto the trial data collection booklet. Once the cae-
sarean section is complete information about the proce-
dure will be recorded by the surgeon who performed the
operation. At discharge from hospital (or transfer to
another hospital) staff on the postnatal ward will record
information about the trial outcomes from hospital
records.
In addition, all women will be seen at six weeks postpar-
tum to determine whether they have experienced any ofPage 10 of 17
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variety of ways: women will be encouraged to return to
the hospital at six weeks postpartum for a routine check-
up at which point trial specific information can also be
requested. Women who do not return at six weeks will be
sought and interviewed by appropriately trained person-
nel employed by the trial either by telephone (if feasible)
or by home visits.
To facilitate the accurate recording of clinical diagnoses
and treatments after hospital discharge women will be
provided with a medical card at discharge from hospital.
Women will ask health professionals who they see after
hospital discharge to record any diagnoses made and
record the treatment prescribed. Although this is unlikely
to be used on all occasions, it should enhance the quality
of the information obtained at the six week interview.
Sufficient descriptive information will be collected about
the participating women in the trial to allow further fol-
low-up if funds can be secured in the future. Of particular
interest in the future is the effect that operative techniques
may have on future pregnancies, specifically problems
with conception, antenatal complications such as the inci-
dence of abruption, mode of delivery especially 'in-
labour' caesarean sections, placental problems, subse-
quent wound complications and stillbirths.
Analysis
The analysis of this trial will be by 'intention-to-treat'.
Therefore women will be analysed by the groups into
which they were randomised regardless of what interven-
tions they received.
For the analysis, the risk ratio for each outcome will be
estimated for each of the five surgical techniques. A 95%
confidence interval will be used for the main outcome
although any results which are of "borderline" statistical
significance will be treated cautiously owing to the five
comparisons being made. For secondary outcomes, 99%
confidence intervals will be calculated in order to take
account of the number of secondary outcomes.
The focus of the analysis will be on the main effects of the
five interventions. However, pairwise interactions
between any two interventions will be tested for and the
results will be stratified accordingly if interactions are
found. Alternatively, if risk differences provide a better fit
to the data than risk ratios, then these will be presented
instead. It is recognised that the study has low power to
detect interactions, therefore, an interaction test which is
not statistically significant does not mean that there really
is no interaction. Alternatively, there are 24 possible inter-
action pairs which can be tested for, so "significant inter-
actions" may arise by chance. Hence, the interaction
results will be interpreted cautiously together with other
evidence such as biological plausibility and consistency
(e.g. across countries).
In addition, pre-defined subgroup analysis will be per-
formed based on outcomes stratified by:
i. 'In-labour' or not 'in-labour' caesarean section,
ii. Single and multiple pregnancy,
iii. HIV positivity (positive, negative, not known),
iv. Number of previous caesarean sections (none or one),
v. Presence of intrapartum fever,
vi. Type of anaesthesia (local, regional, general),
vii. Experience of the operator (number of years experi-
ence in obstetrics),
viii. Centre or Country (numbers permitting).
Further exploratory analysis will be performed to generate
hypotheses for future testing. This will include the effects
of other interventions and techniques used during the
operation and the effect these have on the outcomes.
Interim analyses: the Data Monitoring Committee
For the trial a Data Monitoring Committee (DMC) has
been established. This is independent of the trial organis-
ers. The DMC will meet before the trial commences to
agree their terms of reference and the method of working
using the DMC Charter [26]. During the period of recruit-
ment to the trial, interim analyses will be supplied, in
strict confidence, to the DMC, together with any other
analyses the DMC may request. The data will be supplied
to the Chair of the DMC as frequently as he requests.
Meetings of the committee will be arranged periodically,
as considered appropriate by the Chair but these meetings
will occur at least once a year after trial recruitment com-
mences.
In the light of interim data, and other evidence from rele-
vant studies (including updated overviews of the relevant
randomised controlled trials), the DMC will inform the
Trial Steering Committee, if in their view there is proof
beyond reasonable doubt that the data indicate that any
part of the protocol under investigation is either clearly
indicated or contra-indicated, either for all women or for
a particular subgroup of trial participants. A decision to
inform the Trial Steering Committee of such a finding will
in part be based on statistical considerations.Page 11 of 17
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cannot be specified precisely. A difference of at least 3
standard errors in the interim analysis of a major end-
point may be needed to justify halting, or modifying, such
a study prematurely. If this criterion were to be adopted, it
would have the practical advantage that the exact number
of interim analyses would be of little importance, and so
no fixed schedule is proposed [27]. Unless modification
or cessation of the protocol is recommended by the DMC,
the Trial Steering Committee, collaborators and adminis-
trative staff (except those who supply the confidential
information) will remain ignorant of the results of the
interim analysis. Collaborators and all others associated
with the study may write through the International Co-
ordinating Centre to the DMC, to draw attention to any
concern they may have about the possibility of harm aris-
ing from the treatment under study, or about any other
matters that may be relevant.
Data Monitoring Committee membership
Professor Zarko Alfirevic.
Dr Susan Bewley.
Dr Oona Campbell.
Professor Jon Deeks.
Professor Florence Mirembe.
Serious Adverse Event reporting
Serious Adverse Events should be reported to the
CORONIS Regional Trial Office within 48 hours. The
Regional Trial Office will then notify the International Co-
ordinating Centre in Oxford who will then report it to the
Chair of the DMC and the relevant research ethics com-
mittees, with a summary of the previously reported
events, within 15 days. As all of the surgical techniques
being tested in this trial are used throughout the world
there are no Serious Adverse Events which would be antic-
ipated as a unique consequence of participation in the
trial. We would, however, expect the following to be
reported:
• All maternal deaths;
• Severe haemorrhage (requiring transfusion of six or
more units of blood);
• Repeat laparotomy or hysterectomy;
• Admission to Intensive Care Unit;
• Any other serious unexpected adverse events.
Sample size
In our pilot survey of 855 consecutive women undergoing
caesarean section from 9 hospitals, the incidence of seri-
ous maternal morbidity before discharge from hospital
was 11.6% (95% CI: 9.6–13.9). Inclusion of outcomes up
to six weeks after the caesarean section is therefore likely
to increase the incidence of the primary outcome to at
least 15%. Assuming the incidence of the primary out-
come is 15% in one group, then 7,586 women would
need to be randomised to give 80% power to detect a risk
ratio between the two groups of 0.85 (i.e. a reduction in
incidence to 12.75%; (Table 7). A trial of this size will
have in excess of 95% power to detect a risk ratio of 0.80
(e.g. to compare 15% with 12%).
In order to ensure that there are 7,586 women included in
the analysis of each comparison, a larger number of
women need to be recruited. First, in order to carry out
five comparisons when each centre takes part in only
three, 12,668 women (7,586 × 1.67) would need to be
recruited. Second, allowing for 15% loss to follow-up,
about 14,904 women (12,668/0.85) would need to be
recruited. Hence, the final target sample size is 15,000
women (Table 7).
Feasibility
Women will be recruited by local clinicians prior to their
caesarean section. Each country will have a Regional Co-
ordinator to assist individual centres with data collection.
In the pilot study, data were collected on 855 eligible
women in 9 centres over 40 days (7,800 women/year).
Assuming that 50% of eligible women will consent to join
the trial, between 12 and 16 centres should be sufficient
to complete the trial in three years. The sizes of centres will
vary in different countries, however, and therefore more
centres may be needed. The Regional Co-ordinators of
each country will recruit sufficient hospitals to complete
recruitment within the trial's timescale.
In order to ensure that a similar number of women are
included in each of the five comparisons, the centres will
need to be balanced according to the "combinations" of
the three interventions. For example, if the small centres
were recruiting to intervention 1 (i.e. they were allocated
the following combinations of interventions: 123; 124;
125; 134; 135; 145) and the large centres were recruiting
to intervention 5 then the study may not have enough
power to detect an effect for intervention 1. Therefore, the
combinations of the three interventions will be allocated
so that each intervention is randomised to a similar
number of women.Page 12 of 17
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results
The Chief Investigator will co-ordinate dissemination of
data from this trial.  To safeguard the scientific integrity of
the trial, all proposals for subsidiary studies linked to the
CORONIS Trial should be presented to the Project Man-
agement Group for approval.  All publications from sub-
sidiary studies using data from the original analyses must
be submitted to the Trial Steering Committee (TSC) for
review before publication. Data from the trial will not be
presented in public before the main results are published
without the prior consent of the TSC (see Organisation
below).     
The success of the trial depends on a large number of cli-
nicians and participants. For this reason chief credit for
the results will not be given to the committees or central
organisers but to all who have collaborated and partici-
pated in the study.    
Authorship at the head of the primary results paper will
take the form ‘The CORONIS Trial Collaborative Group’.
This avoids giving undue prominence to any individual.
All contributors to the study will be listed at the end of the
report, with their contribution to the study identified.
This will include all members of the Trial Steering Com-
mittee, the Project Management Group, the International
Co-ordinating Centre, the Regional Trial Offices and local
investigators at all participating sites.    
Those responsible for other publications reporting spe-
cific aspects of the trial may wish to utilise a different
authorship model, such as “[name], [name] and [name]
on behalf of The CORONIS Trial Collaborative Group”.    
Decisions about authorship of additional papers will be
discussed and agreed by the trial investigators. Authorship
of these papers should follow standard academic rules
and should be discussed and agreed by the trial investiga-
tors.  A description of the uniform requirements for man-
uscripts submitted to biomedical journals is available
online (October 2004; http://www.icmje.org/#author).  
The criteria for authorship are:  
· Substantial contributions to conception and design, or
acquisition of data, or analysis and interpretation of data  
· Drafting the article or revising it critically for important
intellectual content  
· Final approval of the version to be published.   All
authors should fulfil all of the criteria for authorship.   
Acquisition of funding, collection of data or general
supervision alone does not of itself justify authorship.  
Presentations given about CORONIS should include an
acknowledgement of the contribution of all the trial
investigators and their organisations and of other collab-
orators and participants.  
Organisation and governance
The protocol received ethics approval in the UK from
OXTREC: Oxford Tropical Research Ethics Committee.
Date of approval: 5th March 2007. OXTREC Reference
number: 013-06. Each country will obtain ethics approval
prior to recruitment commencing.
The trial will be run according to the MRC Good Clinical
Practice guidelines and local data protection require-
ments. The trial will be monitored on a day-to-day basis
in the International Co-ordinating Centre at the National
Perinatal Epidemiology Unit (NPEU). This group reports
to the Trial Steering Committee which is responsible to
the UK Medical Research Council and the University of
Oxford.
The Trial Steering Committee will oversee the conduct of
the trial and will work to a charter agreed by all members.
Trial Steering Committee
The specific tasks of the TSC are:
1. to approve the study protocol,
Table 7: Sample size
Incidence in control group Incidence in intervention group Risk ratio Total sample size needed for analysis
of each comparison
15% 18% 1.20 4,936
15% 17% 1.13 10,746
15% 13% 0.87 9,646
15% 12.75% 0.85 7,586
15% 12% 0.80 4,204
15% 11% 0.73 2,316
Sample sizes required for 15% incidence of primary outcome in control group, with 80% powerPage 13 of 17
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considerations of feasibility and practicability,
3. to receive the report from the Data Monitoring Com-
mittee,
4. to resolve problems brought to it by the International
Co-ordinating Centre,
5. to review and approve add-on studies, including higher
degrees, study reports and papers for publication.
Each Regional Trial Office will report to a Regional Co-
ordinator, who in turn will report to the Project Manage-
ment Group via the project funded staff based at the
NPEU.
Each centre will have a participating clinician, and further
staffing will vary depending on the amount of community
follow-up required.
Trial Steering Committee membership
See Table 8.
International Co-ordinating Centre
The National Perinatal Epidemiology Unit at the Univer-
sity of Oxford will be the International Co-ordinating
Centre and will be responsible for the day to day running
of the trial. The functions include:
i. recruitment of participating centres via the Regional Co-
ordinators,
ii. distribution and supply of data collection forms and
other appropriate documentation for the trial to the
Regional Trial Offices,
iii. central data management,
iv. data cleaning,
v. data analysis,
vi. collection and dissemination of adverse event data,
vii. organising and servicing the Data Monitoring Com-
mittee and the Trial Steering Committee.
Regional Trial Offices
Each country will have a trial office with responsibility to
the Regional Co-ordinator. There will be two trial offices
in India, one in Delhi and one in Vellore. The trial office
will be responsible for one or more participating hospitals
in their country or region. The responsibilities of each trial
office include:
i. recruitment of participating centres,
ii. distribution and supply of data collection forms and
other appropriate documentation for the trial,
iii. local data management,
iv. data entry and cleaning,
v. collection of adverse event data and communication of
this to the International Co-ordinating Centre and else-
where as required,
vi. coordinate documentation of training undertaken by
operators in each of the participating centres.
Participating sites
Local co-ordination in participating sites is the responsi-
bility of a lead clinician in the participating hospital who
is responsible for ensuring the smooth running of the trial
in their unit.
The specific responsibility of the local co-ordinators will
be to:
i. be familiar with the trial,
ii. liaise with their Regional Trial Office,
Table 8: 
Felicity Ashworth Obstetrician Independent member
Peter Brocklehurst Perinatal Epidemiologist Chief Investigator
Simon Cousens Statistician Independent member
Debbie Chippington-Derrick Consumer Representative Independent member
Barbara Farrell Trial Director Observer
James Neilson Obstetrician Chair – Independent member
Manorama Purwar Obstetrician Independent member
Ed Juszczak Trial Statistician Observer
Fiona Russell Programme Manager MRC representative
Catriona Waddington Consumer Representative Independent member
Investigator representative Obstetrician Investigator – in rotationPage 14 of 17
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the care of pregnant women are well informed about the
trial,
iv. ensure that mechanisms for recruitment of eligible
women (including information material) are in place,
monitor their effectiveness, and discuss reasons for the
non-recruitment of any eligible women with relevant
staff,
v. ensure that supplies of data collection booklets are
always available, that they are completed and returned to
the Regional Trial Office promptly, and to deal with any
queries arising,
vi. notify the Regional Trial Office of any serious adverse
events,
vii. facilitate other aspects of local collaboration as appro-
priate,
viii. make all data available for verification, audit and
inspection purposes as necessary,
Argentina
Hospital Nacional Profesor Alejandro Posadas, Illia y
Marconi, Haedo, Buenos Aires, Argentina.
Hospital Interzonal General de Agudoa Dr. Jose Penna,
Lainez 2400, Buenos Aires, Argentina.
Hospital Dr. José María Cullen, Sante Fe, Argentina.
Hospital J. B. Iturraspe, Sante Fe, Argentina.
Hospital Regional Dr. Ramón Carrillo, Belgrano 2273,
Santiago del Estero, Argentina.
Ghana
Komfo Anokye Teaching Hospital, Kumasi, Ghana.
India – (north) Delhi
All India Institute of Medical Sciences (AIIMS), Ansari
Nagar, New Delhi, India.
Maulana Azad Medical College & Lok Nayak Hospital,
New Delhi, India.
Lady Hardinge Medical College & Sucheta Kriplani Hospi-
tal, New Delhi, India.
University College of Medical Sciences & GTB Hospital,
Shahdara, New Delhi, India.
India – (south) Vellore
Christian Medical College Hospital, Vellore, India.
Kenya
Kenyatta National Hospital, Nairobi, Kenya.
Pakistan
Fatima Bai Hospital, Business Recorder Road, Karachi,
Pakistan
Liaquat National Hospital, Stadium Road, Karachi, Paki-
stan
Sobhraj Maternity Hospital, City District Government,
Karachi, Pakistan
Countess of Dufferin Hospital, Chand Bibi Road, Khara-
dar, Karachi, Pakistan
Sudan
Soba University Hospital, Alamarat, Khartoum, Sudan
Omdurman Maternity Hospital, Omdurman, Sudan
Abbreviations
DMC Data Monitoring Committee
ICC International Co-ordinating Centre
NPEU National Perinatal Epidemiology Unit
PPH post partum haemorrhage
RR risk ratio
RTO Regional Trial Office
SD standard deviation
TSC Trial Steering Committee
VAS visual analogue scale
WMD weighted mean difference
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